TechCrunch: OpenAI Researcher Miles Wang Negotiates Launch of $2 Billion AI Pharmaceutical Startup
drug-discovery openai startup
| Source: Mastodon | Original article
OpenAI researcher to launch AI drug discovery startup. The new venture is reportedly valued at $2B.
Miles Wang, a researcher at OpenAI, is leaving the company to launch a new startup focused on AI drug discovery. According to TechCrunch, the startup is in talks to raise funding at a valuation of $2 billion. This development matters because it highlights the growing interest in using AI to accelerate scientific and biological discovery, particularly in the pharmaceutical industry.
The potential of AI in drug discovery is significant, as it can help find new uses for existing drugs and identify promising candidates that may have previously failed in trials. Wang's new venture may be working on AI models that can achieve these goals, posing a notable development in the field.
As the deal is not final, it remains to be seen how Wang's startup will fare, but the reported involvement of Lightspeed as a lead investor suggests significant backing. With Google DeepMind spinout Isomorphic Labs having raised a $2.1 billion Series B in May, the landscape for AI-driven drug discovery is becoming increasingly competitive. What happens next will be worth watching, as Wang's startup could potentially disrupt the pharmaceutical industry and bring new innovations to the forefront.
Sources
Back to AIPULSEN